Skip to main content
Equibles
LYEL logo

LYEL · Lyell Immunopharma, Inc.

Track LYEL — free

Use LYEL with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$14.37 -0.16 (-1.10%) At close · Aug 31
Russell 2000 member Rebalance outlook locked
Market Cap
$356.06M
Shares
24.51M

Press releases and events scraped from the company's investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.

Past events

Date Event Type
2026-08-06 Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2026 Event
2026-06-30 H.C. Wainwright 4th Annual Cell Therapy Virtual Conference Conference
2026-06-25 Lyell Immunopharma Announces Participation in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference Conference
2026-06-12 Lyell Immunopharma Presents Updated Safety Data and Translational Insights for Rondecabtagene Autoleucel (Ronde-Cel) in Patients with Large B-Cell Lymphoma at European Hematology Association 2026 Congress Event
2026-06-08 Goldman Sachs 47th Annual Global Healthcare Conference Conference
2026-06-08 Lyell Immunopharma Provides Update on Safety Profile of LYL273 in Relapsed or Refractory Metastatic Colorectal Cancer and Amends Phase 1 Trial to Phase 1/2 Expansion Event
2026-06-04 Lyell Immunopharma to Present Phase 1/2 Safety and Translational Data for Ronde-Cel in Large B-Cell Lymphoma at the European Hematology Association 2026 Congress Event
2026-06-01 Lyell Immunopharma Announces Participation in Goldman Sachs 47th Annual Global Healthcare Conference 2026 Conference
2026-05-20 2026 Stifel Virtual Targeted Oncology Forum Webcast
2026-05-19 H.C. Wainwright 4th Annual BioConnect Investor Conference Conference
2026-05-12 Lyell Immunopharma Announces Participation in May Investor Conferences Conference
2026-05-06 Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2026 Event
2026-04-14 25th Annual Needham Virtual Healthcare Conference Conference
2026-04-07 Lyell Immunopharma Announces Participation in 25th Annual Needham Virtual Healthcare Conference Conference
2026-03-12 Lyell Immunopharma Reports Q4 and Full Year 2025 Business and Financial Results Event
2026-03-10 Citizens Life Science Conference Conference
2026-03-09 Leerink Annual Global Healthcare Conference Conference
2026-03-09 Lyell Immunopharma Announces Closing of Additional $50 Million Tranche of Equity Private Placement and Appointment of Smital Shah as Chief Financial and Business Officer Event
2026-03-02 TD Cowen 46th Annual Health Care Conference Conference
2026-02-23 Lyell Immunopharma Announces Participation in March Investor Conferences Conference
2025-12-08 Lyell Presents New Ronde-Cel Clinical and Translational Data at ASH 2025 Webcast
2025-11-10 Lyell Strengthens Next-Generation CAR T-Cell Pipeline with Novel GCC-Targeted Product Candidate for Metastatic Colorectal Cancer Webcast
2025-06-17 New Clinical Data from the Phase 1/2 Trial of LYL314 for the Treatment of Aggressive Large B-cell Lymphoma Webcast

Source: https://ir.lyell.com/

Key facts CIK 1806952 CUSIP 55083R203 13F (30d) 90 filings 85 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)